Disparate effects of atorvastatin compared with simvastatin on C-reactive protein concentrations in patients with type 2 diabetes

Diabetes Care

Volumn 33, Issue 9, 2010, Pages 1948-1950

  Sathyapalan, Thozhukat ^a   Atkin, Stephen L ^a   Kilpatrick, Eric S ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN; LETHARGY; LIPID BLOOD LEVEL; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION;

ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; HEPTANOIC ACIDS; HUMANS; PYRROLES; SIMVASTATIN;

EID: 78649922807     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-0201     Document Type: Article

References (15)

1. Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, Roman M, Devereux RB, Fabsitz RR, Tracy RP, Robbins D, Davidson M, Ahmed A, Howard BV. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 2005;112:1289-1295 (Pubitemid 41266723)
2. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005;45:1644-1648 (Pubitemid 40704500)
3. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E, Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352:20-28
4. Ridker PM, Danielson E, Fonseca FA, Genest J, GottoAMJr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-1182
5. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423
6. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 2003;88:1528-1533 (Pubitemid 36623365)
7. Jayagopal V, Kilpatrick ES, Jennings PE, Holding S, Hepburn DA, Atkin SL. The biological variation of sex hormone-binding globulin in type 2 diabetes: implications for sex hormone-binding globulin as a surrogate marker of insulin resistance. Diabetes Care 2004;27:278-280 (Pubitemid 38196751)
8. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-437
9. Sathyapalan T, Atkin SL, Kilpatrick ES. Variability of lipids in patients with type 2 diabetes taking statin treatment: implications for target setting. Diabet Med 2008;25:909-915
10. Morrow DA, de Lemos JA, Sabatine MS, Wiviott SD, Blazing MA, Shui A, Rifai N, Califf RM, Braunwald E. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006;114:281-288
11. Cho LW, Jayagopal V, Kilpatrick ES, Atkin SL. The biological variation of C-reactive protein in polycystic ovarian syndrome. Clin Chem 2005;51:1905-1907 (Pubitemid 41368188)
12. Campbell B, Badrick T, Flatman R, Kanowski D. Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem 2002;39:85-88 (Pubitemid 34214362)
13. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. Highdose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445
14. Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, Cziraky M. Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated. Mayo Clin Proc 2008;83:1316-1325
15. Furberg CD. Natural statins and stroke risk. Circulation 1999;99:185-188 (Pubitemid 29056354)